The shortage of medicines has become one of the major problems to be solved by the health and pharmaceutical authorities. lily will invest 413 million euros (450 in dollars) to expand the production capacity of its facilities in North Carolina And thus facing a high demand for its drugs for diabetes. Plus, it would create “at least 100 new jobs,” says the American.
Lily has a clear list of resolutions for this year. “In 2023, we will be focused on finding innovative solutions to meet the growing demand for our medicines,” said Edgardo Hernandez, Executive Vice President and President of Manufacturing Operations. The expansion of facilities will be fully operational in 2027, On the other hand, it will create at least a hundred new jobs, mainly for manufacturing personnel.
American indicates On track to achieve target of doubling its growth potential (substance-containing diabetes therapy) by the end of this year. Since 2020 it has invested 3.7 billion euros in these facilities. In fact, the company hopes to begin initial production this year in preparation for US Food and Drug Administration (FDA) inspections. In addition, it added that this expansion is “a significant exposure to Lilly’s existing drug supply as it prepares to bring its next generation of medicines to patients around the world.”
loss The problem of shortage exists globally including in Spain., In October 2022, Amps announced that the country was suffering from supply problems in the treatments used for type two diabetes. One of the missing drugs was Lilly’s Trulicity. These were the company’s words: “We ask healthcare professionals not to increase demand, to maintain treatment for patients who have already started, but not to start it with new patients.”
